A Single Arm Clinical Trial to Assess the Efficacy and Safety of Panitumumab (Vectibix®) in combination with FOLFOX4 Chemotherapy as 1st line treatment in Subjects with …

Background: EGFR overexpression occurs in 27–55% of gastroesophageal adenocarcinomas, and correlates with poor prognosis. We aimed to assess the efficacy and safety of the anti-EGFR antibody Panitumumab (PANIT) in addition to Oxaliplatin, 5-FU and Leucovorin (FOLFOX 4) as front-line treatment in patients (pts) with metastatic gastric or gastroesophageal–junction (GEJ) adenocarcinoma. Primary endpoint was response rate (ORR); secondary endpoints were duration of and time to response (DoR and TTR), safety, PFS and OS.